RoundTable to Acquire Symmetry Surgical for $143 Million

| Printer friendly version

Lake Forest, Illinois-based RoundTable Healthcare Partners recently announced an agreement to acquire Symmetry Surgical, Inc.  RoundTable states that the acquisition will provide a new platform in surgical instrumentation and specialty devices.  According to the press release, RoundTable will acquire Symmetry for a total equity value of approximately $140.3 million.  Thomas P. Kapfer, a Senior Operating Partner of RoundTable, will serve as Chairman of the Board of Symmetry.  Regarding the acquisition, Mr. Kapfer stated that:

We are very excited to partner with Symmetry.  The Company’s comprehensive product portfolio is comprised of well-known brands that are recognized by hospitals and physicians worldwide.  We look forward to working with the management team as they continue to serve their customers and grow the business.

Symmetry is a Nashville, Tennessee-based marketer of reusable, reposable, and single-use surgical instrumentation and specialty devices. These devices include a comprehensive variety of surgical instruments, such as calipers, cannulas, curettes, needles, scalpels, specula, and tubes.  The press release states that Symmetry’s portfolios include well-known brands such as BOOKWALTER®, GREENBURG®, OLSEN®, QUAD-LOCK®, RAPID CLEAN®, RILEY MEDICAL®, SHARP KERRISONTM, ULTRA INSTRUMENTS®, and VESOCLUDETM.

Craig Reynolds, the Chairman of Symmetry’s Board of Directors, stated that:

The sale of Symmetry to RoundTable will provide our shareholders with immediate and substantial cash value . . . and is in the best interest of all our stakeholders.

Nasdaq’s GlobNewswire describes RoundTable as a private equity firm focused exclusively on the healthcare industry.  RoundTable partners with companies that can benefit from its industry relationships and operating expertise and has raised $2.75 billion in committed capital.


Robert Hilton
Dr. Robert J. Hilton focuses primarily on patent prosecution in the chemistry and life sciences fields. Robert assists a wide range of clients, including small and large companies locally and internationally. He currently represents clients with technology in the fields of stem cells, CAR T cells, prostate cancer therapeutics and other oncology pharmaceuticals, vaccines, medical devices, dietary supplements, diagnostic devices and assays, cosmetics, and therapeutic antibodies. Robert earned his Ph.D. in biochemistry from BYU. His research involved the studies of metals in biological systems, including metal dysregulation in diseases such as chronic kidney disease.
Click here to read full bio
View all posts published by Robert Hilton »

Leave a Reply

By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.